How the treatment of AML will change
Mary Frances McMullin
COMy 2017: Day 1 discussion on progress in multiple myeloma, patient advocacy and drug costs
Arnon Nagler et al.
Pros and cons of combination therapy for multiple myeloma
Is venetoclax appropriate for relapsed CLL patients?
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors